This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Augmedix Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Manny Krakaris

Amministratore delegato

US$919.1k

Compenso totale

Percentuale dello stipendio del CEO	49.9%
Mandato del CEO	6yrs
Proprietà del CEO	0.1%
Durata media del management	4.8yrs
Durata media del Consiglio di amministrazione	3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jun 19

Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

May 21

Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Apr 25

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Mar 24

Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov 09

Augmedix reports Q2 results

Aug 08

Augmedix: A Splendid Long-Term Investing Opportunity

Jan 21

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Manny Krakaris rispetto agli utili di Augmedix?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$24m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$919k	US$459k	-US$19m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$1m	US$450k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$400k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$16m
Dec 31 2020	US$634k	US$296k	-US$16m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$18m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$511k	US$350k	-US$18m

Compensazione vs Mercato: La retribuzione totale di Manny ($USD 919.10K ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.72K ).

Compensazione vs guadagni: La retribuzione di Manny è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Manny Krakaris (65 yo)

6yrs

Mandato

US$919,099

Compensazione

Mr. Emmanuel Krakaris, also known as Manny, is President, Secretary and Director of Augmedix, Inc. since October 2018 and is its Chief Executive Officer since October 2018. Mr. Krakaris served as the Chie...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Emmanuel Krakaris	President	6yrs	US$919.10k	0.13% $ 152.2k
Ian Shakil	Founder	no data	US$818.06k	0.020% $ 23.6k
Sandra Breber	Chief Operating Officer	5.6yrs	US$651.09k	0.041% $ 47.7k
Paul Ginocchio	Chief Financial Officer	4.3yrs	Nessun dato	0.27% $ 319.1k
Saurav Chatterjee	Chief Technology Officer	3.9yrs	US$633.35k	0.012% $ 13.7k
Todd Holvick	Head of Legal & Compliance	no data	Nessun dato	Nessun dato
Lia Wallick	Head of People	5.4yrs	Nessun dato	Nessun dato
Davin Lundquist	Chief Medical Officer	4.8yrs	Nessun dato	Nessun dato
Jonathan Hawkins	Chief Revenue Officer	5.5yrs	US$440.01k	0.012% $ 13.7k
Tomer Levy	Senior Vice President of Engineering	less than a year	Nessun dato	Nessun dato
Alex Stinard	Chief Clinical AI Officer	less than a year	Nessun dato	Nessun dato

4.8yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di AUGX è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Emmanuel Krakaris	President	6yrs	US$919.10k	0.13% $ 152.2k
Ian Shakil	Founder	11.5yrs	US$818.06k	0.020% $ 23.6k
William Febbo	Independent Director	2.6yrs	US$181.29k	0.33% $ 382.1k
Roderick O'Reilly	Independent Non-Executive Chairman of the Board	1.6yrs	US$548.26k	0.044% $ 50.8k
Jason Krikorian	Independent Director	7.4yrs	US$200.00k	0.15% $ 174.4k
Robert Faulkner	Independent Director	1.5yrs	US$128.44k	0.084% $ 97.4k
Laurie McGraw	Lead Independent Director	2.6yrs	US$210.64k	0.15% $ 174.4k
Margie Traylor	Independent Director	3.4yrs	US$190.64k	0.25% $ 291.7k

3.0yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AUGX sono considerati esperti (durata media dell'incarico 3 anni).

This company has been acquired

Augmedix Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Augmedix Appoints Alex Stinard as Chief Clinical AI Officer

Founder notifies of intention to sell stock

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

High number of new directors

Augmedix, Inc., Annual General Meeting, Jul 13, 2023

Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product Development

Recent updates

Augmedix's Stock Ceases Trading and to be Delisted from the Nasdaq Stock Market

Commure, Inc. completed the acquisition of Augmedix, Inc. (NasdaqCM:AUGX) from a group of shareholders.

Second quarter 2024 earnings: EPS misses analyst expectations

Augmedix, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million.

Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million.

Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024

Augmedix Appoints Alex Stinard as Chief Clinical AI Officer

Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations

Augmedix, Inc. Provides Revenue Guidance for the Year 2024

Price target increased by 12% to US$6.83

Now 26% overvalued

Augmedix, Inc. to Report Q1, 2024 Results on May 13, 2024

Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go

Augmedix, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Now 21% undervalued after recent price drop

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

Now 22% overvalued after recent price rise

Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Augmedix, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.0% to US$7.63

Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Augmedix, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target increased by 12% to US$7.13

High number of new directors

Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician Controlled Mobile App

Augmedix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Augmedix, Inc., Annual General Meeting, Jul 13, 2023

Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product Development

Joseph W. Marks to Resign from the Augmedix's Board of Directors Effective on the Date of 2023 Annual Meeting of Stockholders

Augmedix, Inc. Provides Revenue Guidance for the Year 2023

Augmedix, Inc. to Report Q1, 2023 Results on May 12, 2023

Augmedix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Augmedix, Inc. announced delayed 10-Q filing

Augmedix, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Augmedix Launches New Service, Augmedix Prep, to Significantly Reduce Physician Chart Prep Burden

Augmedix, Inc. Announces Resignation of Gerard Van Hamel Platerink as Director

Augmedix reports Q2 results

Augmedix - Trio Health - CIIC Announce the Launch of an Innovative Platform

Augmedix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Augmedix, Inc. to Report Q1, 2022 Results on May 09, 2022

Augmedix, Inc. Names William Febbo as New Member to its Board of Directors

Augmedix: A Splendid Long-Term Investing Opportunity

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media